Cas:52644-01-6 5,6-dimethoxy-3,4-dihydro-1H-naphthalen-2-one manufacturer & supplier

Chemical Name:5,6-dimethoxy-3,4-dihydro-1H-naphthalen-2-one

CAS.NO:52644-01-6

Synonyms:5,6-dimethoxy-3,4-dihydronaphthalen-2(1H)-one;5,6-dimethoxy-3,4-dihydro-2(1H)-naphthalenone;5,6-dimethoxytetralin-2-one

Molecular Formula:C₁₂H₁₄O₃

Molecular Weight:206.23800

HS Code:2914509090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:35.53000

Exact Mass:206.09400

LogP:1.76160

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5,6-dimethoxy-3,4-dihydronaphthalen-2(1H)-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5,6-dimethoxytetralin-2-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5,6-dimethoxytetralin-2-one Use and application,5,6-dimethoxy-3,4-dihydronaphthalen-2(1H)-one technical grade,usp/ep/jp grade.

Related News: It found that about 5% of both groups of women have a genetic mutation that increases the risk of breast cancer. 5,6-dimethoxy-3,4-dihydro-1H-naphthalen-2-one manufacturer First of all, as an API manufacturer we think of how to make a chemical compound which becomes an API in the laboratory. 5,6-dimethoxy-3,4-dihydro-1H-naphthalen-2-one supplier Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. 5,6-dimethoxy-3,4-dihydro-1H-naphthalen-2-one vendor Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. 5,6-dimethoxy-3,4-dihydro-1H-naphthalen-2-one factory Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma.